Home
SAB Biotherapeutics

SAB Biotherapeutics Market Share Analysis for June 2026

SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent...

Industry: N/A

Domainsab.bio

Year Founded2014

Employees51 - 200

Annual Revenue$1M - $2M

SAB Biotherapeutics

SAB Biotherapeutics (including company regionals)

sab.bio

See more website traffic and engagement information

SAB Biotherapeutics Revenue up to June 2026 is 1M - 2M

revenue generated by SAB Biotherapeutics top domains

SAB Biotherapeutics top domains revenue over 3 years

Revenue for SAB Biotherapeutics top domains

sab.bio1M - 2M

See more with Sales Intelligence

Total visits to SAB Biotherapeutics's top domains

Understand SAB Biotherapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

sab.bio18.8K

See more with Sales Intelligence

Avg. visit duration in SAB Biotherapeutics's top domains

Analyze SAB Biotherapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

sab.bio00:03:30

See more with Sales Intelligence

Avg. pageviews on SAB Biotherapeutics's top domains

See how SAB Biotherapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

sab.bio2.64

See more with Sales Intelligence

SAB Biotherapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by SAB Biotherapeutics

These are the website technologies, by industry, used by SAB Biotherapeutics top domains

Mobile (2)

Meta Viewport

Audio Video Media (1)

Vimeo

Business Solutions (1)

DocuSign

Content Management System (1)

WordPress

More Technologies

7

See all

News & Signals from SAB Biotherapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSAB Biotherapeutics, Inc. will attend event 2026 Scientific Sessions on Jun 5th '26.SAB BIO will present an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association(R)(ADA) being held June 5-8, 2026, in New Orleans, LA.

NewsEmergent Testing, LLC partnered with SAB Biotherapeutics, Inc. on Oct 27th '22.GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) - Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support the process development and manufacturing of SAB-142, SAB BIO's lead program in clinical development for autoimmune type 1 diabetes (T1D).

NewsEmergent BioSolutions Inc. partnered with SAB Biotherapeutics, Inc. on Apr 29th '26.GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) - Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support the process development and manufacturing of SAB-142, SAB BIO's lead program in clinical development for autoimmune type 1 diabetes (T1D).